‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

The Federal Trade Commission and seven states say Shkreli should be held in contempt

Summary from the MarketWatch news feed. Copyright belongs to MarketWatch.

Opens in a new tab, so Investz stays open.

ShareEmail X LinkedIn Facebook Reddit WhatsApp

More headlines

CNBCTrump's diesel deal with Russia equals less than two weeks of U.S. demand CNBCJ&J posts weak medical device sales, shares fall CNBCBank earnings takeaways: Here's how JPMorgan, Goldman, Wells Fargo and Citi performed in Q3 CNBCWhy this little known Chinese chipmaker has caused a global stock rout CNBCStocks making the biggest moves midday: Apple, Meta Platforms, Bumble, Fermi, Goldman Sachs & more CNBCCNBC Points Pro: How to book a flight to South Africa with points

Headlines and summaries come from publishers’ public news feeds and are shown with attribution and a link to the original. Investz does not write or endorse them and they are not investment advice. Disclosures.